| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Veterans Affairs Medical Center, Department of Medicine, University of California, San Diego, CA 92161;
Department of Surgery, College of Physicians and Surgeons, Columbia University, New York, NY 10032;
Novartis Institutes for Biomedical Research, Cambridge, MA 02139; and
The Scripps Research Institute, La Jolla, CA 92037
The multiligand receptor for advanced glycation end products (RAGE) mediates certain chronic vascular and neurologic degenerative diseases accompanied by low-grade inflammation. RAGE ligands include S100/calgranulins, a class of low-molecular-mass, calcium-binding polypeptides, several of which are chondrocyte expressed. Here, we tested the hypothesis that S100A11 and RAGE signaling modulate osteoarthritis (OA) pathogenesis by regulating a shift in chondrocyte differentiation to hypertrophy. We analyzed human cartilages and cultured human articular chondrocytes, and used recombinant human S100A11, soluble RAGE, and previously characterized RAGE-specific blocking Abs. Normal human knee cartilages demonstrated constitutive RAGE and S100A11 expression, and RAGE and S100A11 expression were up-regulated in OA cartilages studied by immunohistochemistry. CXCL8 and TNF-
induced S100A11 expression and release in cultured chondrocytes. Moreover, S100A11 induced cell size increase and expression of type X collagen consistent with chondrocyte hypertrophy in vitro. CXCL8-induced, IL-8-induced, and TNF--induced but not retinoic acid-induced chondrocyte hypertrophy were suppressed by treatment with soluble RAGE or RAGE-specific blocking Abs. Last, via transfection of dominant-negative RAGE and dominant-negative MAPK kinase 3, we demonstrated that S100A11-induced chondrocyte type X collagen expression was dependent on RAGE-mediated p38 MAPK pathway activation. We conclude that up-regulated chondrocyte expression of the RAGE ligand S100A11 in OA cartilage, and RAGE signaling through the p38 MAPK pathway, promote inflammation-associated chondrocyte hypertrophy. RAGE signaling thereby has the potential to contribute to the progression of OA.
This article has been cited by other articles:
|
|
 |
|
  D. L. Cecil, C. T. G. Appleton, M. D. Polewski, J. S. Mort, A. M. Schmidt, A. Bendele, F. Beier, and R. Terkeltaub The Pattern Recognition Receptor CD36 Is a Chondrocyte Hypertrophy Marker Associated with Suppression of Catabolic Responses and Promotion of Repair Responses to Inflammatory Stimuli J. Immunol., April 15, 2009; 182(8): 5024 - 5031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Cecil and R. Terkeltaub Transamidation by Transglutaminase 2 Transforms S100A11 Calgranulin into a Procatabolic Cytokine for Chondrocytes J. Immunol., June 15, 2008; 180(12): 8378 - 8385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Esposito, J. Imitola, J. Lu, D. De Filippis, C. Scuderi, V. S. Ganesh, R. Folkerth, J. Hecht, S. Shin, T. Iuvone, et al. Genomic and functional profiling of human Down syndrome neural progenitors implicates S100B and aquaporin 4 in cell injury Hum. Mol. Genet., February 1, 2008; 17(3): 440 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sakaguchi, H. Sonegawa, H. Murata, M. Kitazoe, J.-i. Futami, K. Kataoka, H. Yamada, and N.-h. Huh S100A11, an Dual Mediator for Growth Regulation of Human Keratinocytes Mol. Biol. Cell, January 1, 2008; 19(1): 78 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Zen, C. X.-J. Chen, Y.-T. Chen, R. Wilton, and Y. Liu Receptor for Advanced Glycation Endproducts Mediates Neutrophil Migration across Intestinal Epithelium J. Immunol., February 15, 2007; 178(4): 2483 - 2490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fyhrie, F. R.T. Nelson, and G. Gibson On the Horizon From the ORS. J. Am. Acad. Ortho. Surg., April 1, 2006; 14(4): 256 - 258. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
